Risk of hip fracture associated with hepatitis c virus infection and hepatitis C/human immunodeficiency virus coinfection

Hepatology

Volumn 56, Issue 5, 2012, Pages 1688-1698

  Lo Re, Vincent ^a,b   Volk, Jessica ^c   Newcomb, Craig W ^b   Yang, Yu Xiao ^a,b   Freeman, Cristin P ^b   Hennessy, Sean ^b   Kostman, Jay R ^a   Tebas, Pablo ^a   Leonard, Mary B ^b   Localio, A Russell ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HIP FRACTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; ANTI-RETROVIRAL AGENTS; BONE DENSITY; CASE-CONTROL STUDIES; COINFECTION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIP FRACTURES; HIV INFECTIONS; HUMANS; INCIDENCE; LIVER FAILURE; MALE; MEDICAID; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; UNITED STATES; YOUNG ADULT;

EID: 84868191819     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25866     Document Type: Article

References (44)

1. Seeff LB. Natural history of chronic hepatitis C. HEPATOLOGY 2002;36: S35-S46.
2. El-Serag HB, Hampel H, Yeh C, Rabeneck L. Extrahepatic manifestations of hepatitis C among United States male veterans HEPATOLOGY 2002;36:1439-1445.
3. Gallego-Rojo FJ, Gonzalez-Calvin JL, Munoz-Torres M, Mundi JL, Fernandez-Perez R, Rodrigo-Moreno D. Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. HEPATOLOGY 1998;28:695-699.
4. Gonzalez-Calvin JL, Gallego-Rojo F, Fernandez-Perez R, Casado-Caballero F, Ruiz-Escolano E, Olivares EG. Osteoporosis, mineral metabolism, and serum soluble tumor necrosis factor receptor p55 in viral cirrhosis. J Clin Endocrinol Metab 2004;89:4325-4330.
5. Leslie WD, Bernstein CN, Leboff MS. AGA technical review on osteoporosis in hepatic disorders. Gastroenterology 2003;125:941-966.
6. Lo Re V, 3rd, Guaraldi G, Leonard MB, Localio AR, Lin J, Orlando G, et al. Viral hepatitis is associated with reduced bone mineral density in HIV-infected women but not men. AIDS 2009;23:2191-2198.
7. Rouillard S, Lane NE. Hepatic osteodystrophy. HEPATOLOGY 2001;33: 301-307.
8. Gilbert L, He X, Farmer P, Rubin J, Drissi H, van Wijnen AJ, et al. Expression of the osteoblast differentiation factor RUNX2 (Cbfa1/ AML3/Pebp2alpha A) is inhibited by tumor necrosis factor-alpha. J Biol Chem 2002;277:2695-2701.
9. Hay JE. Bone disease in cholestatic liver disease. Gastroenterology 1995;176-283.
10. Pignata S, Daniele B, Galati MG, Esposito G, Vallone P, Fiore F, et al. Oestradiol and testosterone blood levels in patients with viral cirrhosis and hepatocellular carcinoma. Eur J Gastroenterol Hepatol 1997;9: 283-286.
11. McComsey GA, Tebas P, Shane E, Yin MT, Overton ET, Huang JS, et al. Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis 2010;51:937-946.
12. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006;20: 2165-2174.
13. Mittalhenkle A, Gillen DL, Stehman-Breen CO. Increased risk of mortality associated with hip fracture in the dialysis population. Am J Kidney Dis 2004;44:672-679.
14. Hennessy S, Carson JL, Ray WA, Strom BL.: Medicaid databases. In: Strom BL, ed. Pharmacoepidemiology, 4th ed. Chichester, UK: Wiley; 2005.
15. Centers for Medicare and Medicaid Services. Medicaid Statistical Information System (MSIS) Tables. http://www.cms.gov/MedicaidDataSourcesGenInfo/MSIS/list.asp. Available at: Accessed on April 4, 2012.
16. Centers for Medicare and Medicaid Services. Medicaid Analytic eXtract (MAX) Validation Reports. http://www.cms.gov/Medicaid-DataSourcesGenInfo/MVR/list.asp. Available at: Accessed on April 4, 2012.
17. Medicare Payment Advisory Commission. Report to the Congress: New Approaches in Medicare. 2004.
18. Hennessy S, Leonard CE, Palumbo CM, Newcomb C, Bilker WB. Quality of Medicaid and Medicare data obtained through Centers for Medicare and Medicaid Services (CMS). Med Care 2007;45: 1216-1220.
19. Keyes M, Andrews R, Mason ML. A methodology for building an AIDS research file using Medicaid claims and administrative data bases. J Acquir Immune Defic Syndr 1991;4:1015-1024.
20. Kramer JR, Davila JA, Miller ED, Richardson P, Giordano TP, El-Serag HB. The validity of viral hepatitis and chronic liver disease diagnoses in Veterans Affairs administrative databases. Aliment Pharmacol Ther 2008;27:274-282.
21. Markowitz JS, Gutterman EM, Hodes D, Klaskala W. Factors associated with the initiation of alpha-interferon treatment in Medicaid patients diagnosed with hepatitis C. J Viral Hepat 2005;12:176-185.
22. Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, Telenti A, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010;304:321-333.
23. Hofmann WP, Kronenberger B, Bojunga J, Stamm B, Herrmann E, Bucker A, et al. Prospective study of bone mineral density and metabolism in patients with chronic hepatitis C during pegylated interferon alpha and ribavirin therapy. J Viral Hepat 2008;15:790-796.
24. Ray WA, Griffin MR, Fought RL, Adams ML. Identification of fractures from computerized Medicare files. J Clin Epidemiol 1992;45: 703-714.
25. Lo Re V, 3rd, Lim JK, Goetz MB, Tate J, Bathulapalli H, Klein MB, et al. Validity of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort Study. Pharmacoepidemiol Drug Saf 2011;20:689-699.
26. Little RJA. Direct standardization: a tool for teaching linear models for unbalanced data. Am Stat 1982;36:38-43.
27. Braitman LE, Rosenbaum PR. Rare outcomes, common treatments: analytic strategies using propensity scores. Ann Intern Med 2002;137: 693-695.
28. D'Agostino RB, Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265-2281.
29. Collett D. Modeling Survival Data in Medical Research. New York: Chapman and Hall; 2003.
30. Lee BK, Lessler J, Stuart EA. Weight trimming and propensity score weighting. PLoS One 2011;6:e18174.
31. Rosenbaum PR, Rubin DB. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat 1985;39:33-38.
32. Lin DY, Psaty BM, Kronmal RA. Assessing the sensitivity of regression results to unmeasured confounders in observational studies. Biometrics 1998;54:948-963.
33. Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non- HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab 2008;93:3499-3504.
34. Fakruddin JM, Laurence J. HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kappa B ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-gamma/RANKL cross-talk. J Biol Chem 2003;278:48251-48258.
35. Gibellini D, De Crignis E, Ponti C, Cimatti L, Borderi M, Tschon M, et al. HIV-1 triggers apoptosis in primary osteoblasts and HOBIT cells through TNFalpha activation. J Med Virol 2008;80:1507-1514.
36. Mondy K, Yarasheski K, Powderly WG, Whyte M, Claxton S, DeMarco D, et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis 2003;36:482-490.
37. Tebas P, Powderly WG, Claxton S, Marin D, Tantisiriwat W, Teitelbaum SL, Yarasheski KE. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 2000;14:F63-F67.
38. Brown TT, McComsey GA, King MS, Qaqish RB, Bernstein BM, da Silva BA. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr 2009;51:554-561.
39. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004;292:191-201.
40. Fux CA, Christen A, Zgraggen S, Mohaupt MG, Furrer H. Effect of tenofovir on renal glomerular and tubular function. AIDS 2007;21: 1483-1485.
41. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 2010.
42. Fleishman JA, Gebo KA, Reilly ED, Conviser R, Christopher Mathews W, Todd Korthuis P, et al. Hospital and outpatient health services utilization among HIV-infected adults in care 2000-2002. Med Care 2005; 43(9 Suppl):III40-III52.
43. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144:705-714.
44. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002;34:831-837